173 related articles for article (PubMed ID: 28401314)
1. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
Wang XJ; Goh DYT; Dorajoo SR; Chan A
Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
5. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
[TBL] [Abstract][Full Text] [Related]
7. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
8. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
[TBL] [Abstract][Full Text] [Related]
10. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
Bitar RA
Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
[TBL] [Abstract][Full Text] [Related]
11. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
12. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
14. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
16. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
18. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]